Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izencitinib SAD/MAD in Healthy Subjects
NCT02657122Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Dec 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of izencitinib in ulcerative colitis (UC) and Crohn's disease (4 arms), sponsored by Theravance Biopharma, Inc. Primary endpoint: Safety and tolerability of SAD and MAD of TD-1473. Started Dec 2015; status: completed.
02
Drugs
izencitinib
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT02657122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657122.